Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
作者信息
Koch Marcus
机构信息
Clinical Neurosciences, University of Calgary, Calgary, AB T2N 1N4, Canada
出版信息
J Neurol Neurosurg Psychiatry. 2024 Apr 12;95(5):391. doi: 10.1136/jnnp-2023-332758.
PMID:37963724
Abstract
摘要
Zotero 插件